Published in J Cell Biol on May 19, 1997
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol (2000) 1.51
Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific. J Physiol (2006) 1.15
Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol (2004) 1.10
Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. J Biol Chem (2010) 1.03
Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol (1998) 1.03
Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol (2007) 1.00
Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther (2013) 0.98
Differential sensitivity of mouse epithelial tissues to the polyomavirus middle T oncogene. Am J Pathol (2006) 0.81
Common and specific effects of TIE2 mutations causing venous malformations. Hum Mol Genet (2015) 0.80
PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res (2014) 0.77
Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator. Cytotechnology (2005) 0.75
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
Studies on the character and staining of fibrin. J Clin Pathol (1962) 6.54
Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 4.40
The plasminogen activator/plasmin system. J Clin Invest (1991) 4.20
Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev (1995) 2.81
Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med (1984) 2.78
Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell (1990) 2.77
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation (1995) 2.38
Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell (1988) 2.36
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest (1993) 2.20
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest (1993) 2.08
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A (1996) 1.66
The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem (1995) 1.45
Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst (1995) 1.13
Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein (1996) 1.09
Proteolytic balance and capillary morphogenesis. Cell Differ Dev (1990) 1.09
Oncogenes in the study of endothelial cell growth and differentiation. Semin Cancer Biol (1994) 1.09
Oncogenic properties of the middle T antigens of polyomaviruses. Adv Cancer Res (1994) 1.07
Endothelial cell transformation by polyomavirus middle T antigen in mice lacking Src-related kinases. Curr Biol (1994) 0.95
Mice with hemangiomas induced by transgenic endothelial cells. A model for the Kasabach-Merritt syndrome. Am J Pathol (1994) 0.83
Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells. Blood (1994) 0.78
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature (1988) 13.21
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (1995) 8.12
Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors. Nature (1985) 7.54
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell (1993) 7.14
c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science (1994) 5.97
Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64
In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med (2001) 5.54
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Strain-dependent epithelial defects in mice lacking the EGF receptor. Science (1995) 5.22
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 5.19
Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature (1997) 5.08
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev (1999) 4.75
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development (1992) 4.69
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev (1995) 4.54
Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A (1997) 4.52
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res (1999) 4.23
Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature (1982) 4.22
Bone and haematopoietic defects in mice lacking c-fos. Nature (1993) 4.07
Molecular mechanisms of blood vessel growth. Cardiovasc Res (2001) 3.94
AP-1 in mouse development and tumorigenesis. Oncogene (2001) 3.93
Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell (1994) 3.91
Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A (1987) 3.88
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci (1998) 3.80
Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (1989) 3.80
IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res (1998) 3.74
Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem (1995) 3.69
Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A (1986) 3.68
The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem (1996) 3.53
Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev (1999) 3.51
c-jun is essential for normal mouse development and hepatogenesis. Nature (1993) 3.43
Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A (1986) 3.42
Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet (1999) 3.42
Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci U S A (1998) 3.35
Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol (1994) 3.31
Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem (1995) 3.30
Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol (1999) 3.29
PARP is important for genomic stability but dispensable in apoptosis. Genes Dev (1997) 3.20
The human beta-globin gene and a functional viral thymidine kinase gene in developing mice. Proc Natl Acad Sci U S A (1981) 2.93
In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol (1983) 2.91
Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell (1990) 2.77
Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system. Blood (1996) 2.76
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood (1997) 2.71
Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol (1998) 2.71
Cigarette smoking, major depression, and other psychiatric disorders among adolescents. J Am Acad Child Adolesc Psychiatry (1996) 2.69
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res (1996) 2.65
Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol (2000) 2.61
Transfer of genes into embryonal carcinoma cells by retrovirus infection: efficient expression from an internal promoter. EMBO J (1985) 2.60
JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr Biol (1999) 2.60
Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell (1985) 2.58
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res (1996) 2.58
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol (1999) 2.56
Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev (1999) 2.56
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
Role of tissue factor in embryonic blood vessel development. Nature (1996) 2.54
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost (2003) 2.49
The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature (1994) 2.49
HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev (1997) 2.47
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med (2001) 2.46
Heterogeneous distribution of filipin--cholesterol complexes across the cisternae of the Golgi apparatus. Proc Natl Acad Sci U S A (1981) 2.45
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development (2000) 2.43
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A (2001) 2.42
Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res (1993) 2.39
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation (1995) 2.38
Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med (2000) 2.36
Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell (1988) 2.36
Differentiation of F9 teratocarcinoma stem cells after transfer of c-fos proto-oncogenes. Nature (1984) 2.34
Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol (1998) 2.34
Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res (1995) 2.33
Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development (1997) 2.32
Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J (2001) 2.32
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A (1998) 2.32
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci (1997) 2.28
Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol (1997) 2.27
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun (1991) 2.25
Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer (1994) 2.24
Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res (1995) 2.23